Calithera Biosciences

Calithera is pioneering the discovery and development of targeted, small molecule therapies to treat cancer and other life threatening diseases.

[Calithera Biosciences @calithera]

Yesterday, we announced the expansion of our clinical-stage #oncology pipeline with the acquisition of sapanisertib and mivavotinib from @TakedaPharma. Read the press release announcing this important milestone for more information. https://t.co/tn3WNKagk9

[Calithera Biosciences @calithera]

Do you know your NSCLC patient’s KEAP1 status?
~ 1 in 5 individuals with NSCLC have a mutated KEAP1/NRF2 pathway.
Find out if your patient is eligible for the KEAPSAKE trial combining telaglenastat with chemoimmunotherapy in first line patients. https://t.co/WBjQfc5cDV

[KCCure @kcCURE]

Less than 4% of oncology trials result in regulatory approval. Great reward requires risk. Thank you @calithera and @ExelixisInc for your willingness to invest in #kidneycancer.

[Calithera Biosciences @calithera]

Today we reported topline results from the Phase 2 CANTATA study and provided an update on corporate strategy. https://t.co/wkd1I9Jw1V

[Calithera Biosciences @calithera]

Wishing everyone a Happy New Year and auspicious start to 2021! We look forward to what this year will bring for our company, our exceptional employees, and the people we exist to help - patients, their loved ones, and the medical professionals who care for them.

[Calithera Biosciences @calithera]

#DYK Mutations in the KEAP1/NRF2 pathway, which occur in an estimated 20% of non-small cell #lungcancer patients, are associated with aggressive tumor growth? Learn more about Calithera’s efforts to develop a therapy that uniquely targets this pathway. https://t.co/XmHXRii9aj

[Calithera Biosciences @calithera]

If you've recently received a #kidneycancer diagnosis, know that you are not alone. The @KidneyCancer Just Diagnosed toolkit has a variety of helpful resources, including a step-by-step guide and specialist finder. https://t.co/JvmELzDLJY

[Calithera Biosciences @calithera]

We love a challenge - especially if we get to solve it together! Our recent Chopped Challenge gave Calithera team members a chance to show off their culinary and creative skills, turning 4 surprise ingredients into amazing dishes.

[Calithera Biosciences @calithera]

We're fully "on board" with this proposal, @NASDAQ. A big part of Calithera's strength is that we have always been fully invested in diversity at all levels. https://t.co/F4SiEriyJK

[Calithera Biosciences @calithera]

For many, a #kidneycancer diagnosis can feel like an overwhelming and isolating experience. @kcCURE offers online & virtual support groups to connect people w/ similar experiences and diagnoses. Check them out here. https://t.co/SHrGCfc1eq

[Calithera Biosciences @calithera]

#DYK Mutations in the KEAP1/NRF2 pathway, which occur in an estimated 20% of non-small cell #lungcancer patients, are associated with aggressive tumor growth? Learn more about Calithera’s efforts to develop a therapy that uniquely targets this pathway. https://t.co/XmHXRii9aj

[Cystic Fibrosis Foundation @CF_Foundation]

Today, we announced a new research award of up to $2.4M to Calithera Biosciences Inc. to advance a potential treatment to reduce infections in the lungs of people with #cysticfibrosis. #CFresearch https://t.co/q0Prwz7Ngg

[Calithera Biosciences @calithera]

Curiosity, transparency, connectedness and focus are at the core of who we are at Calithera. If these values align with yours and you are energized by scientific innovation, check out our job listings and consider submitting your resume. $CALA
https://t.co/CdWOJThpE6

[Calithera Biosciences @calithera]

#News Today we announced our trial in progress poster at the North American Cystic Fibrosis Conference. It describes the design of the trial evaluating our arginase inhibitor CB-280. $CALA #NACFC #cysticfibrosis
https://t.co/4ydvWBmtgC

[Calithera Biosciences @calithera]

Congratulations to $CALA Board Member Deepa Pakianathan for being selected as an innovation leader by the @uspto National Council for #ExpandingAmericanInnovation, which is developing a comprehensive nat’l strategy to expand opportunities and fuel U.S. #innovation.

[Calithera Biosciences @calithera]

#DYK #CysticFibrosis affects more than 30,000 people worldwide. There is an urgent need to improve therapies for this devastating disease.$CALA https://t.co/lG2S3LXyP9

[Calithera Biosciences @calithera]

Scott Garland joins our board of directors. Welcome!
https://t.co/GL3nc6HTUA

[Calithera Biosciences @calithera]

Calithera is pleased to announce CB-280 trial initiation in people with cystic fibrosis.
https://t.co/B1yMfAwg55
#CF #CysticFibrosis #lung #arginase #inhibitor

[IKCC Kidney Cancer @IKCCorg]

Today is World Kidney Cancer Day! Being physically active can reduce your risk of #kidneycancer by up to 22%. If you already have kidney cancer, even moderate physical activity can improve treatment outcomes by up to 15%.
#rcc #mrcc #physicalactivity #exercise